

CHAPTER ONE: INTRODUCTION.....	1
STUDY OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ABOUT THE AUTHOR.....	3
RELATED BCC RESEARCH REPORTS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
EXECUTIVE SUMMARY.....	5
<i>SUMMARY TABLE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, THROUGH 2015 (\$ BILLIONS)</i>	6
<i>SUMMARY FIGURE WORLDWIDE REVENUE OF AUTACOIDS AND RELATED PRODUCTS, 2008-2015 (\$ BILLIONS)</i>	6
 CHAPTER THREE: OVERVIEW.....	 7
DEFINITION.....	7
GENERAL CHARACTERISTICS OF AUTACOIDS.....	7
CLASSIFICATION OF AUTACOIDS.....	7
BIOGENIC AMINE.....	8
Histamine.....	8
Roles/ Functions of Histamine.....	9
Serotonin.....	10
Roles of Serotonin.....	10
Catecholamines.....	11
Functions of Catecholamine.....	12
POLYPEPTIDE AUTACOIDS.....	13
Angiotensin.....	14
Functions of Angiotensin.....	14
Kinins.....	15
Functions of Kinins.....	15
Vasoactive Intestinal Polypeptide.....	16
Functions of Vasoactive Intestinal Polypeptide.....	16
Natriuretic Peptides.....	17
Functions of Natriuretic Peptides.....	17
ENDOTHELIUM-DERIVED AUTACOIDS.....	18
Endothelins.....	18
Functions of Endothelins.....	19
Nitric Oxide.....	19
Functions of Nitric Oxide.....	19
LIPID-DERIVED AUTACOIDS.....	20

Eicosanoids	20
Functions of Eicosanoids	21
Platelet Activating Factor	22
Functions of Platelet-Activating Factor.....	22
CHAPATER FOUR: DRUGS RELATED TO AUTACOIDS	23
<i>FIGURE 1 CLASSIFICATION OF DRUGS RELATED TO AUTACOIDS</i>	23
BIOGENIC AMINES	24
HISTAMINE DRUGS	24
H1 Receptor Antagonists.....	24
<i>TABLE 1 H1 RECEPTOR ANATAGONISTS</i>	25
H2 Antagonists	26
<i>TABLE 2 H2 RECEPTOR ANATAGONISTS</i>	26
H3 and H4 Receptor Antagonists	26
SEROTONIN DRUGS.....	27
Serotonin-Norepinephrine Reuptake Inhibitors	27
<i>TABLE 3 SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS</i>	28
Selective Serotonin Reuptake Inhibitors (SSRIs)	28
<i>TABLE 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS</i>	29
Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors	29
Serotonin Receptor Agonists	30
<i>TABLE 5 SEROTONIN RECEPTOR AGONISTS</i>	30
Serotonin Receptor Antagonists	30
<i>TABLE 6 SEROTONIN RECEPTOR ANTAGONISTS</i>	31
CATECHOLAMINES.....	31
Directly Acting Sympathomimetic Drugs.....	32
<i>TABLE 7 DIRECTLY ACTING SYMPATHOMIMETIC DRUGS</i>	32
<i>TABLE 7 (CONTINUED)</i>	33
Indirectly Acting Sympathomimetic Drugs.....	34
<i>TABLE 8 INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS</i>	34
Adrenolytics	35
<i>TABLE 9 ADRENOLYTICS</i>	35
Dopaminergic Antagonists/Dopamine Receptor Antagonists.....	36
<i>TABLE 10 DOPAMINE ANTAGONISTS</i>	36
POLYPEPTIDE AUTACOIDS.....	37
ANGIOTENSIN DRUGS	37
Angiotensin II Receptor Antagonists.....	37
<i>TABLE 11 ANGIOTENSIN II RECEPTOR ANTAGONISTS</i>	38
Angiotensin-Converting Enzymes (ACE) Inhibitors.....	38
<i>TABLE 12 ANGIOTENSIN CONVERTING ENZYME INHIBITORS</i>	38
KININS.....	39
DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE.....	39

<i>TABLE 13 DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE</i>	40
DRUGS RELATED TO ENDOTHELIUM-DERIVED AUTACOIDS	40
ENDOTHELIN RECEPTOR ANTAGONISTS	40
<i>TABLE 14 ENDOTHELIN RECEPTOR ANTAGONISTS</i>	40
NITRIC OXIDE	40
<i>TABLE 15 PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE</i>	41
DRUGS RELATED TO LIPID-DERIVED AUTACOIDS.....	41
EICOSANOID DRUGS	41
<i>TABLE 16 EICOSANOID, EICOSANOID ANALOGS AND RECEPTOR AGONISTS/ANTAGONISTS</i>	42
<i>TABLE 16 (CONTINUED)</i>	43
PLATELET-ACTIVATING FACTOR.....	43
<i>TABLE 17 PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS</i>	43
CHAPTER FIVE: REGULATORY ASPECTS	44
APPROVALS OF DRUGS RELATED TO AUTACOIDS	44
<i>TABLE 18 NEW AND GENERIC DRUG APPROVALS OF THE DRUGS RELATED TO AUTACOIDS, 2006–2009</i>	44
<i>TABLE 18 (CONTINUED)</i>	45
<i>TABLE 18 (CONTINUED)</i>	46
<i>TABLE 18 (CONTINUED)</i>	47
<i>TABLE 18 (CONTINUED)</i>	48
<i>TABLE 19 NEW DRUG APPLICATIONS OF THE DRUGS RELATED TO AUTACOIDS</i>	49
<i>TABLE 19 (CONTINUED)</i>	50
<i>TABLE 20 SAFETY ALERTS, 2006–2009</i>	50
CHAPTER SIX: INDUSTRY STRUCTURE.....	51
MARKET LEADERS WITH THEIR PRODUCTS IN BIOGENIC AMINES.....	51
<i>TABLE 21 LEADING MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS</i>	51
<i>TABLE 22 LEADING MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS</i>	51
<i>TABLE 23 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS</i>	52
<i>TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS</i>	52
<i>TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR AGONISTS</i>	52
<i>TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR ANTAGONISTS</i>	53

<i>TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING SYMPATHOMIMETIC DRUGS.....</i>	<i>53</i>
<i>TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS.....</i>	<i>54</i>
<i>TABLE 29 LEADING MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS.....</i>	<i>54</i>
<i>TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS.....</i>	<i>54</i>
<i>MARKET LEADERS WITH THEIR PRODUCTS IN POLYPEPTIDE AUTACOIDS.....</i>	<i>55</i>
<i>TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS</i>	<i>55</i>
<i>TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.....</i>	<i>55</i>
<i>TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDE.....</i>	<i>56</i>
<i>MARKET LEADERS WITH THEIR PRODUCTS IN ENDOTHELIUM DERIVED AUTACOIDS</i>	<i>56</i>
<i>TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS.....</i>	<i>56</i>
<i>TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGS OF NITRIC OXIDE MARKET</i>	<i>56</i>
<i>MARKET LEADERS WITH THEIR PRODUCTS IN LIPID DERIVED AUTACOIDS.....</i>	<i>57</i>
<i>TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF EICOSANOIDS.....</i>	<i>57</i>
<i>TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS</i>	<i>57</i>
<i>MARKET SHARES OF INDUSTRY LEADERS</i>	<i>58</i>
<i>BIOGENIC AMINES</i>	<i>58</i>
<i>H1 Receptor Antagonists.....</i>	<i>58</i>
<i>TABLE 38 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>58</i>
<i>FIGURE 2 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H1 RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>59</i>
<i>H2 Receptor Antagonists.....</i>	<i>59</i>
<i>TABLE 39 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>60</i>
<i>FIGURE 3 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF H2 RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>60</i>

Serotonin Norepinephrine Reuptake Inhibitors	61
<i>TABLE 40 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN</i>	
<i>NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%)</i>	61
<i>FIGURE 4 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN</i>	
<i>NOREPINEPHRINE REUPTAKE INHIBITORS, 2009 (%)</i>	61
Selective Serotonin Reuptake Inhibitors	62
<i>TABLE 41 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN</i>	
<i>REUPTAKE INHIBITORS, 2009 (%)</i>	62
<i>FIGURE 5 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SELECTIVE SEROTONIN</i>	
<i>REUPTAKE INHIBITORS, 2009 (%)</i>	63
Serotonin Receptor Agonists Market	63
<i>TABLE 42 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR</i>	
<i>AGONISTS, 2009 (%)</i>	63
<i>FIGURE 6 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR</i>	
<i>AGONISTS, 2009 (%)</i>	64
Serotonin Receptor Antagonists Market	64
<i>TABLE 43 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR</i>	
<i>ANTAGONISTS, 2009 (%)</i>	65
<i>FIGURE 7 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF SEROTONIN RECEPTOR</i>	
<i>ANTAGONISTS, 2009 (%)</i>	65
Directly Acting Sympathomimetic Drugs	65
<i>TABLE 44 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF DIRECTLY ACTING</i>	
<i>SYMPATHOMIMETICS, 2009 (%)</i>	66
<i>FIGURE 8 DIRECTLY ACTING SYMPATHOMIMETICS, 2009 (%)</i>	66
Indirectly Acting Sympathomimetic Drugs	67
<i>TABLE 45 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING</i>	
<i>SYMPATHOMIMETICS, 2009 (%)</i>	67
<i>FIGURE 9 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF INDIRECTLY ACTING</i>	
<i>SYMPATHOMIMETICS, 2009 (%)</i>	68
Adrenolytics	68
<i>TABLE 46 WORLDWIDE MARKET SHARES OF</i>	
<i>MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%)</i>	69

<i>FIGURE 10 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ADRENOLYTICS, 2009 (%).....</i>	<i>69</i>
Dopamine Antagonists	70
<i>TABLE 47 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%).....</i>	<i>70</i>
<i>FIGURE 11 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DOPAMINE ANTAGONISTS, 2009 (%).....</i>	<i>70</i>
POLYPEPTIDE AUTACOIDS.....	71
Angiotensin II Receptor Antagonists.....	71
<i>TABLE 48 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>71</i>
<i>FIGURE 12 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>72</i>
Angiotensin-Converting Enzyme Inhibitors.....	72
<i>TABLE 49 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN- CONVERTING ENZYME INHIBITORS, 2009 (%).....</i>	<i>73</i>
<i>FIGURE 13 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN- CONVERTING ENZYME INHIBITORS, 2009 (%).....</i>	<i>73</i>
Drugs Related to Vasoactive Intestinal Polypeptides.....	74
<i>TABLE 50 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%).....</i>	<i>74</i>
<i>FIGURE 14 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2009 (%).....</i>	<i>74</i>
ENDOTHELIUM-DERIVED AUTACOIDS.....	75
Endothelin Receptor Antagonists	75
<i>TABLE 51 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>75</i>
<i>FIGURE 15 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ENDOTHELIN RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>75</i>
Pharmaceutical Analogues of Nitric Oxide	76
<i>TABLE 52 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%).....</i>	<i>76</i>

<i>FIGURE 16 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PHARMACEUTICAL ANALOGUES OF NITRIC OXIDE, 2009 (%).....</i>	<i>76</i>
LIPID-DERIVED AUTACOIDS	77
Eicosanoids	77
<i>TABLE 53 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%).....</i>	<i>77</i>
<i>FIGURE 17 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF EICOSANOIDS, 2009 (%).....</i>	<i>78</i>
Platelet Activating Factor Receptor Antagonists.....	78
<i>TABLE 54 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>78</i>
<i>FIGURE 18 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2009 (%).....</i>	<i>79</i>
CHAPTER SEVEN: NEW DEVELOPMENTS.....	80
<i>TABLE 55 NEW DEVELOPMENTS IN THE FIELD OF HISTAMINE ANTAGONISTS.....</i>	<i>80</i>
<i>TABLE 56 NEW DEVELOPMENTS IN THE FIELD OF SEROTONIN ANTAGONISTS.....</i>	<i>81</i>
<i>TABLE 56 (CONTINUED).....</i>	<i>82</i>
<i>TABLE 56 (CONTINUED).....</i>	<i>83</i>
<i>TABLE 57 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE AGONISTS.....</i>	<i>83</i>
<i>TABLE 58 NEW DEVELOPMENTS IN THE FIELD OF ADRENERGIC AGONISTS.....</i>	<i>84</i>
<i>TABLE 59 NEW DEVELOPMENTS IN THE FIELD OF ADRENOLYTICS.....</i>	<i>85</i>
<i>TABLE 59 (CONTINUED).....</i>	<i>86</i>
<i>TABLE 60 NEW DEVELOPMENTS IN THE FIELD OF DOPAMINE ANTAGONISTS.....</i>	<i>87</i>
<i>TABLE 60 (CONTINUED).....</i>	<i>88</i>
<i>TABLE 61 NEW DEVELOPMENTS IN THE FIELD OF ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS.....</i>	<i>88</i>
<i>TABLE 61 (CONTINUED).....</i>	<i>89</i>
<i>TABLE 62 NEW DEVELOPMENTS IN THE FIELD OF VASOACTIVE INTESTINAL POLYPEPTIDE INHIBITORS</i>	<i>89</i>
<i>TABLE 62 (CONTINUED).....</i>	<i>90</i>
<i>TABLE 63 NEW DEVELOPMENTS IN THE FIELD OF ENDOTHELIN ANTAGONISTS.....</i>	<i>90</i>
<i>TABLE 64 NEW DEVELOPMENTS IN THE FIELD OF EICOSANOIDS</i>	<i>91</i>
<i>TABLE 64 (CONTINUED).....</i>	<i>92</i>

CHAPTER EIGHT: MARKET ANALYSIS.....	93
TABLE 65 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, THROUGH 2015 (\$ BILLIONS)	93
FIGURE 19 WORLDWIDE MARKET FOR AUTACOIDS BY REGION, 2008-2015 (\$ BILLIONS).....	94
MARKET SHARES OF AUTACOIDS MARKET, BY REGION	94
TABLE 66 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%).....	95
FIGURE 20 WORLDWIDE AUTACOIDS MARKET SHARES BY REGION, 2009 (%).....	95
DRUGS RELATED TO BIOGENIC AMINES.....	95
TABLE 67 WORLDWIDE MARKET FOR BIOGENIC AMINES, THROUGH 2015 (\$ MILLIONS).....	96
FIGURE 21 WORLDWIDE MARKET FOR BIOGENIC AMINES, 2008- 2015 (\$ MILLIONS).....	96
HISTAMINES	97
TABLE 68 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, THROUGH 2015 (\$ MILLIONS).....	97
FIGURE 22 WORLDWIDE MARKET FOR DRUGS RELATED TO HISTAMINES, 2008-2015 (\$ MILLIONS).....	97
H1 and H2 Receptor Anatagonist	98
Market Overview	98
Market Revenue.....	98
TABLE 69 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS).....	99
FIGURE 23 WORLDWIDE MARKET FOR H1 RECEPTOR ANATAGONISTS, 2008-2015 (\$ MILLIONS).....	99
TABLE 70 WORLDWIDE MARKET FOR H2 RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS).....	100
FIGURE 24 WORLDWIDE MARKET FOR H2 RECEPTOR ANATAGONISTS, 2008-2015 (\$ MILLIONS)	100
SEROTONINS.....	101
TABLE 71 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, THROUGH 2015 (\$ MILLIONS)	101
FIGURE 25 WORLDWIDE MARKET FOR DRUGS RELATED TO SEROTONINS, 2008-2015 (\$ MILLIONS).....	102
Serotonin Norepinephrine Reuptake Inhibitors	102
Market Overview	102
Market Revenue.....	103
TABLE 72 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, THROUGH 2015 (\$ MILLIONS).....	104

<i>FIGURE 26 WORLDWIDE MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2008-2015 (\$ MILLIONS)</i>	104
Serotonin Reuptake Inhibitors.....	105
Market Overview	105
Market Revenue.....	105
<i>TABLE 73 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, THROUGH 2015 (\$ MILLIONS)</i>	106
<i>FIGURE 27 WORLDWIDE MARKET FOR SEROTONIN REUPTAKE INHIBITORS, 2008-2015 (\$ MILLIONS)</i>	106
Serotonin Receptor Agonists	107
Market Overview	107
Market Revenue.....	107
<i>TABLE 74 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	108
<i>FIGURE 28 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR AGONISTS, 2008-2015 (\$ MILLIONS)</i>	108
Serotonin Receptor Antagonists	109
Market Overview	109
Market Revenue.....	109
<i>TABLE 75 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	110
<i>FIGURE 29 WORLDWIDE MARKET FOR SELECTIVE SEROTONIN RECEPTOR ANTAGONISTS, 2008-2015 (\$ MILLIONS)</i>	110
CATECHOLAMINE DRUGS.....	110
<i>TABLE 76 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, THROUGH 2015 (\$ MILLIONS)</i>	111
<i>FIGURE 30 WORLDWIDE MARKET FOR DRUGS RELATED TO CATECHOLAMINES, 2008- 2015 (\$ MILLIONS)</i>	111
Directly Acting Sympathomimetic Drugs.....	112
Market Overview	112
Market Revenue.....	112
<i>TABLE 77 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 (\$ MILLIONS)</i>	113
<i>FIGURE 31 WORLDWIDE MARKET FOR DIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 (\$ MILLIONS)</i>	113
Indirectly Acting Sympathomimetic Drugs.....	114
Market Overview	114
Market Revenue.....	115
<i>TABLE 78 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, THROUGH 2015 (\$ MILLIONS)</i>	116
<i>FIGURE 32 WORLDWIDE MARKET FOR INDIRECTLY ACTING SYMPATHOMIMETIC DRUGS, 2008-2015 (\$ MILLIONS)</i>	116
Adrenolytics	117

Market Overview	117
Market Revenue.....	117
<i>TABLE 79 WORLDWIDE MARKET FOR ADRENOLYTICS, THROUGH 2015 (\$ MILLIONS)</i>	118
<i>FIGURE 33 WORLDWIDE MARKET FOR ADRENOLYTIC, 2008-2015 (\$ MILLIONS)</i>	118
Dopamine Antagonists	118
Market Overview	118
Market Revenue.....	119
<i>TABLE 80 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	119
<i>FIGURE 34 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS, 2008-2015 (\$ MILLIONS)</i>	120
DRUGS RELATED TO POLYPEPTIDE AUTACOIDS	120
<i>TABLE 81 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, THROUGH 2015 (\$ MILLIONS)</i>	121
<i>FIGURE 35 WORLDWIDE MARKET FOR DRUGS RELATED TO POLYPEPTIDE AUTACOIDS, 2008-2015 (\$ MILLIONS)</i>	121
ANGIOTENSIN DRUGS	122
<i>TABLE 82 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, THROUGH 2015 (\$ MILLIONS)</i>	122
<i>FIGURE 36 WORLDWIDE MARKET FOR ANGIOTENSIN DRUGS, 2008-2015 (\$ MILLIONS)</i>	122
Angiotensin II Receptor Antagonists.....	123
Market Overview	123
Market Revenue.....	124
<i>TABLE 83 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	124
<i>FIGURE 37 WORLDWIDE MARKET FOR ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2008-2015 (\$ MILLIONS)</i>	124
Angiotensin-Converting Enzyme (ACE) Inhibitors	125
Market Overview	125
Market Revenue.....	125
<i>TABLE 84 WORLDWIDE MARKET FOR ANGIOTENSIN- CONVERTING ENZYME INHIBITORS, THROUGH 2015 (\$ MILLIONS)</i>	126
<i>FIGURE 38 WORLDWIDE MARKET FOR ANGIOTENSIN- CONVERTING ENZYME INHIBITORS, 2008-2015 (\$ MILLIONS)</i>	126
VASOACTIVE INTESTINAL POLYPEPTIDE	127
Market Overview	127
Market Revenue	127
<i>TABLE 85 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, THROUGH 2015 (\$ MILLIONS)</i>	127

<i>FIGURE 39 WORLDWIDE MARKET FOR DRUGS RELATED TO VASOACTIVE INTESTINAL POLYPEPTIDES, 2008-2015 (\$ MILLIONS)</i>	128
<i>ENDOTHELIUM-DERIVED AUTACOIDS</i>	128
<i>TABLE 86 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, THROUGH 2015 (\$ MILLIONS)</i>	128
<i>FIGURE 40 WORLDWIDE MARKET FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2008-2015 (\$ MILLIONS)</i>	129
<i>ENDOTHELIN RECEPTOR ANTAGONISTS</i>	129
Market Overview	129
Market Revenue	130
<i>TABLE 87 WORLDWIDE MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	130
<i>FIGURE 41 WORLDWIDE MARKET FOR FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2008-2015 (\$ MILLIONS)</i>	131
<i>NITRIC OXIDE</i>	131
Market Revenue	131
<i>TABLE 88 WORLDWIDE MARKET FOR NITRIC OXIDE, THROUGH 2015 (\$ MILLIONS)</i>	132
<i>FIGURE 42 WORLDWIDE MARKET FOR FOR NITRIC OXIDE, 2008-2015 (\$ MILLIONS)</i>	132
<i>DRUGS RELATED TO LIPID-DERIVED AUTACOIDS</i>	132
<i>TABLE 89 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, THROUGH 2015 (\$ MILLIONS)</i>	133
<i>FIGURE 43 WORLDWIDE MARKET FOR LIPID-DERIVED AUTACOIDS, 2008-2015 (\$ MILLIONS)</i>	133
<i>EICOSANOIDS</i>	134
Market Overview	134
Market Revenue	134
<i>TABLE 90 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, THROUGH 2015 (\$ MILLIONS)</i>	135
<i>FIGURE 44 WORLDWIDE MARKET FOR DRUGS RELATED TO EICOSANOIDS, 2008-2015 (\$ MILLIONS)</i>	135
<i>PLATELET-ACTIVATING FACTOR (PAF) RECEPTOR ANTAGONISTS</i>	136
Market Overview	136
Market Revenue	136
<i>TABLE 91 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, THROUGH 2015 (\$ MILLIONS)</i>	137
<i>FIGURE 45 WORLDWIDE MARKET FOR PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS, 2008-2015 (\$ MILLIONS)</i>	137
<i>MARKET SHARES OF AUTACOIDS MARKET, BY TYPE</i>	138

<i>TABLE 92 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%)</i>	138
<i>FIGURE 46 WORLDWIDE AUTACOIDS MARKET SHARES BY TYPE, 2009 (%)</i>	138
CHAPTER NINE: MARKET BY APPLICATIONS.....	139
MARKET SHARE OF APPLICATIONS.....	139
<i>TABLE 93 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009 (%)</i>	140
<i>FIGURE 47 SHARE OF VARIOUS SECTORS IN AUTACOIDS-RELATED DRUGS, 2009</i>	140
RESPIRATORY DISEASES.....	140
MARKET REVENUE.....	141
<i>TABLE 94 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	142
<i>FIGURE 48 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN RESPIRATORY DISEASES, 2008-2015 (\$ MILLIONS)</i>	142
<i>TABLE 95 SALES OF TOP-SELLING RESPIRATORY DRUGS, 2009 (%)</i>	143
CARDIOVASCULAR DISEASES.....	143
MARKET REVENUE.....	143
<i>TABLE 96 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	144
<i>FIGURE 49 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CARDIOVASCULAR DISEASES, 2008-2015 (\$ MILLIONS)</i>	145
<i>TABLE 97 SALES OF TOP-SELLING CARDIOVASCULAR DRUGS, 2009 (%)</i>	145
CENTRAL NERVOUS SYSTEM DISEASES.....	146
MARKET REVENUE.....	146
<i>TABLE 98 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	147
<i>FIGURE 50 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN CENTRAL NERVOUS SYSTEM, 2008-2015 (\$ MILLIONS)</i>	147
<i>TABLE 99 TOP-SELLING CENTRAL NERVOUS SYSTEM DRUGS IN THE ORDER OF SALES, 2009</i>	148
GASTROINTESTINAL DISORDERS.....	148
MARKET REVENUE.....	148
<i>TABLE 100 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	149
<i>FIGURE 51 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS IN GASTROINTESTINAL DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	149
<i>TABLE 101 TOP-SELLING GASTROINTESTINAL DRUGS IN THE ORDER OF THEIR SALES, 2009</i>	150
ANTIEMETICS.....	150
MARKET REVENUE.....	150

<i>TABLE 102 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 (\$ MILLIONS)</i>	151
<i>FIGURE 52 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANTIEMETICS, THROUGH 2015 (\$ MILLIONS)</i>	151
<i>TABLE 103 TOP-SELLING ANTIEMETICS IN THE ORDER OF THEIR SALES, 2009</i>	152
<i>ANALGESICS</i>	152
<i>MARKET REVENUE</i>	152
<i>TABLE 104 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, THROUGH 2015 (\$ MILLIONS)</i>	153
<i>FIGURE 53 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED AS ANALGESICS, 2008-2015 (\$ MILLIONS)</i>	153
<i>OPHTHALMIC</i>	154
<i>MARKET REVENUE</i>	154
<i>TABLE 105 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	154
<i>FIGURE 54 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED IN OPHTHALMIC DISEASES, 2008-2015 (\$ MILLIONS)</i>	155
<i>TABLE 106 TOP-SELLING OPHTHALMIC DRUGS IN THE ORDER OF SALES, 2009</i>	155
<i>OTHERS</i>	156
<i>MARKET REVENUE</i>	156
<i>TABLE 107 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	156
<i>FIGURE 55 GLOBAL SALES OF AUTACOIDS-RELATED DRUGS USED TO TREAT OTHER DISEASES, THROUGH 2015 (\$ MILLIONS)</i>	157
CHAPTER TEN: PATENT ANALYSIS	158
<i>PATENTS BY YEAR</i>	158
<i>TABLE 108 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006– 2010 (FEB.)</i>	159
<i>FIGURE 56 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2006– 2010 (FEB.)</i>	160
<i>FIGURE 57 NUMBER OF PATENTS BY YEAR, 2006–2010 (FEB.)</i>	160
<i>FIGURE 57 (CONTINUED)</i>	161
<i>PATENTS BY TECHNOLOGY</i>	161
<i>TABLE 109 PATENTS BY TECHNOLOGY, 2006–2010 (FEB.)</i>	161
<i>FIGURE 58 PATENTS BY TECHNOLOGY, 2006–2010 (FEB.)</i>	162
<i>PATENTS BY TYPE</i>	162
<i>BIOGENIC AMINES</i>	162
<i>TABLE 110 PATENTS FOR BIOGENIC AMINES, 2006–2010 (FEB.)</i>	162
<i>FIGURE 59 PATENTS FOR BIOGENIC AMINES, 2006–2010 (FEB.)</i>	163
<i>POLYPEPTIDE AUTACOIDS</i>	163

TABLE 111 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006–2010 (FEB.).....	163
FIGURE 60 PATENTS FOR POLYPEPTIDE AUTACOIDS, 2006–2010 (FEB.).....	164
LIPID-DERIVED AUTACOIDS	164
TABLE 112 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006–2010 (FEB.).....	164
FIGURE 61 PATENTS FOR LIPID-DERIVED AUTACOIDS, 2006–2010 (FEB.).....	165
ENDOTHELIUM-DERIVED AUTACOIDS.....	165
TABLE 113 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006–2010 (FEB.)	165
FIGURE 62 PATENTS FOR ENDOTHELIUM-DERIVED AUTACOIDS, 2006–2010 (FEB.).....	166
PATENTS BY COMPANY.....	166
HISTAMINES	166
TABLE 114 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006–2010 (FEB.)	167
FIGURE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR HISTAMINES, 2006–2010 (FEB.)	168
SEROTONINS.....	168
TABLE 115 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006–2010 (FEB.).....	169
FIGURE 64 NUMBER OF U.S. PATENTS BY COMPANY FOR SEROTONINS, 2006–2010 (FEB.).....	169
CATECHOLAMINES.....	170
TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006–2010 (FEB.).....	170
FIGURE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR CATECHOLAMINES, 2006–2010 (FEB.).....	171
ACE INHIBITORS	171
TABLE 117 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006–2010 (FEB.).....	171
FIGURE 66 NUMBER OF U.S. PATENTS BY COMPANY FOR ACE INHIBITORS, 2006–2010 (FEB.).....	172
ANGIOTENSIN RECEPTOR BLOCKERS.....	172
TABLE 118 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–2010 (FEB.).....	172
FIGURE 67 NUMBER OF U.S. PATENTS BY COMPANY FOR ANGIOTENSIN RECEPTOR BLOCKERS, 2006–2010 (FEB.).....	173
VASOACTIVE INTESTINAL POLYPEPTIDES	173
TABLE 119 NUMBER OF U.S. PATENTS BY COMPANY FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.).....	173

<i>FIGURE 68 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–20100 (FEB.)</i>	174
<i>PLATELET-ACTIVATING FACTOR INHIBITORS</i>	174
<i>TABLE 120 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.)</i>	174
<i>EICOSANOIDS</i>	174
<i>TABLE 121 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>EICOSANOIDS, 2006–2010 (FEB.)</i>	175
<i>FIGURE 69 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>EICOSANOIDS, 2006–2010 (FEB.)</i>	176
<i>ENDOTHELIN RECEPTOR ANTAGONISTS</i>	176
<i>TABLE 122 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.)</i>	177
<i>FIGURE 70 NUMBER OF U.S. PATENTS BY COMPANY FOR</i>	
<i>ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.)</i>	177
<i>PATENTS BY COUNTRY</i>	177
<i>HISTAMINES</i>	177
<i>TABLE 123 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>HISTAMINES, 2006–2010 (FEB.)</i>	178
<i>FIGURE 71 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>HISTAMINES, 2006–2010 (FEB.)</i>	178
<i>SEROTONINS</i>	178
<i>TABLE 124 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>SEROTONINS, 2006–2010 (FEB.)</i>	179
<i>FIGURE 72 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>SEROTONINS, 2006–2010 (FEB.)</i>	179
<i>CATECHOLAMINES</i>	180
<i>TABLE 125 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>CATECHOLAMINES, 2006–2010 (FEB.)</i>	180
<i>FIGURE 73 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>CATECHOLAMINES, 2006–2010 (FEB.)</i>	181
<i>ANGIOTENSIN II RECEPTOR BLOCKERS</i>	181
<i>TABLE 126 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>ANGIOTENSIN II RECEPTOR BLOCKERS, 2006–2010 (FEB.)</i>	181
<i>FIGURE 74 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>ANGIOTENSIN II RECEPTOR BLOCKERS, 2006–2010 (FEB.)</i>	182
<i>ACE INHIBITORS</i>	182
<i>TABLE 127 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE</i>	
<i>INHIBITORS, 2006–2010 (FEB.)</i>	182
<i>FIGURE 75 NUMBER OF U.S. PATENTS BY COUNTRY FOR ACE</i>	
<i>INHIBITORS, 2006–2010 (FEB.)</i>	183
<i>VASOACTIVE INTESTINAL POLYPEPTIDES</i>	183
<i>TABLE 128 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i>VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.)</i>	183

<i>FIGURE 76 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.)</i>	<i>184</i>
<i> PLATELET-ACTIVATING FACTOR INHIBITORS</i>	<i>184</i>
<i>TABLE 129 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.)</i>	<i>184</i>
<i>FIGURE 77 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.)</i>	<i>185</i>
<i> EICOSANOIDS</i>	<i>185</i>
<i>TABLE 130 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> EICOSANOIDS, 2006–2010 (FEB.)</i>	<i>186</i>
<i>FIGURE 78 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> EICOSANOIDS, 2006–2010 (FEB.)</i>	<i>186</i>
<i> ENDOTHELIN RECEPTOR ANTAGONISTS</i>	<i>187</i>
<i>TABLE 131 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.)</i>	<i>187</i>
<i>FIGURE 79 NUMBER OF U.S. PATENTS BY COUNTRY FOR</i>	
<i> ENDOTHELIN RECEPTOR ANTAGONISTS, 2006–2010 (FEB.)</i>	<i>187</i>
<i> PATENTS BY ASSIGNEE</i>	<i>188</i>
<i> HISTAMINES</i>	<i>188</i>
<i>TABLE 132 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006–2010</i>	
<i> (FEB.)</i>	<i>188</i>
<i>FIGURE 80 PATENTS BY ASSIGNEE FOR HISTAMINES, 2006–2010</i>	
<i> (FEB.)</i>	<i>188</i>
<i> SEROTONINS</i>	<i>189</i>
<i>TABLE 133 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006–2010</i>	
<i> (FEB.)</i>	<i>189</i>
<i>FIGURE 81 PATENTS BY ASSIGNEE FOR SEROTONINS, 2006–2010</i>	
<i> (FEB.)</i>	<i>189</i>
<i> CATECHOLAMINES</i>	<i>190</i>
<i>TABLE 134 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006–</i>	
<i> 2010 (FEB.)</i>	<i>190</i>
<i>FIGURE 82 PATENTS BY ASSIGNEE FOR CATECHOLAMINES, 2006–</i>	
<i> 2010 (FEB.)</i>	<i>190</i>
<i> ACE INHIBITORS</i>	<i>191</i>
<i>TABLE 135 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006–</i>	
<i> 2010 (FEB.)</i>	<i>191</i>
<i>FIGURE 83 PATENTS BY ASSIGNEE FOR ACE INHIBITORS, 2006–</i>	
<i> 2010 (FEB.)</i>	<i>191</i>
<i> ANGIOTENSIN RECEPTOR BLOCKERS</i>	<i>192</i>
<i>TABLE 136 PATENTS BY ASSIGNEE FOR ANGIOTENSIN RECEPTOR</i>	
<i> BLOCKERS, 2006–2010 (FEB.)</i>	<i>192</i>
<i>FIGURE 84 PATENTS BY ASSIGNEE FOR ANGIOTENSIN</i>	
<i> RECEPTOR BLOCKERS, 2006–2010 (FEB.)</i>	<i>192</i>
<i> VASOACTIVE INTESTINAL POLYPEPTIDES</i>	<i>193</i>

<i>TABLE 137 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.)</i>	193
<i>FIGURE 85 PATENTS BY ASSIGNEE FOR VASOACTIVE INTESTINAL POLYPEPTIDES, 2006–2010 (FEB.)</i>	193
PLATELET-ACTIVATING FACTOR INHIBITORS	194
<i>TABLE 138 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.)</i>	194
<i>FIGURE 86 PATENTS BY ASSIGNEE FOR PLATELET-ACTIVATING FACTOR INHIBITORS, 2006–2010 (FEB.)</i>	194
EICOSANOIDS	195
<i>TABLE 139 PATENTS BY ASSIGNEE FOR EICOSANOIDS, 2006–2010 (FEB.)</i>	195
<i>FIGURE 87 PATENTS BY ASSIGNEE FOR EICASANOIDS, 2006–2010 (FEB.)</i>	195
ENDOTHELIN RECEPTOR ANTAGONISTS	196
<i>TABLE 140 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006–2010 (FEB.)</i>	196
<i>FIGURE 88 PATENTS BY ASSIGNEE FOR ENDOTHELIN RECEPTOR ANATAGONISTS, 2006–2010 (FEB.)</i>	196
 CHAPTER ELEVEN: CURRENT SITUATION OF AUTACOID-RELATED DRUGS	
FACTS ABOUT AUTACOID-RELATED DRUGS.....	197
FACTORS AFFECTING THE SALES OF AUTACOID-RELATED DRUGS.....	198
COMPETITION.....	198
COST.....	198
PATENT EXPIRATIONS.....	199
<i>TABLE 141 PATENT EXPIRATIONS</i>	200
MAJOR FACTORS FOR FUTURE GROWTH	200
LIFE EXPECTANCY	200
PATENT PROTECTION.....	201
DRUGS PORTFOLIO MANAGEMENT	201
STRATEGIES OF PHARMACEUTICAL COMPANIES.....	201
PATENT EXTENSIONS.....	201
MERGERS, ACQUISITIONS AND COLLABORATIONS	202
PRESCRIPTION TO OVER-THE-COUNTER SWITCHING	202
DIRECT-TO-CONSUMER ADVERTISING	203
APPEAL FOR GENERIC DRUG MANUFACTURING	203
 CHAPTER TWELVE: COMPANY PROFILES	
ABBOTT LABORATORIES.....	204
ACTELION PHARMACEUTICALS LTD.	204
ALCON INC.	205
ALLERGAN INC.....	206

APOTEX	206
APP PHARMA.....	207
ASTRAZENECA PLC	208
AUROBINDO PHARMA.....	209
BAXTER INTERNATIONAL INC.	209
BAYER HEALTHCARE	210
BEDFORD LABORATORIES	210
BIOVAIL CORPORATION.....	210
BOEHRINGER INGELHEIM	211
BRISTOL-MYERS SQUIBB	212
CHATTEM INC.....	212
CIPLA LTD.	213
CYPRESS BIOSCIENCE, INC.....	213
DAIICHI SANKYO CO. LTD.	214
DAVA PHARMCEUTICALS INC.	214
DEY PHARMA, L.P.	215
DR. REDDY'S LABORATORIES LIMITED	215
ELI LILLY & CO.....	216
FOREST LABORATORIES INC.....	217
GILEAD SCIENCES INC.....	217
GLAXO SMITH KLINE PLC	218
HELSINN HEALTHCARE S.A.	219
HOSPIRA INC.	220
IPSEN S.A.	220
JAZZ PHARMACEUTICALS INC.	221
JOHNSON & JOHNSON	222
KING PHARMACEUTICALS INC.	222
MERCK & CO. INC.	223
MYLAN LABS	224
NOVARTIS AG	225
NUVO RESEARCH INC.....	226
NYCOMED US INC.....	226
PAR PHARMACEUTICAL COMPANIES INC.	227
PEDINOL PHARMACAL, INC.	228
PERRIGO COMPANY	228
PFIZER INC.	229
PROSTRAKAN GROUP PLC	229
ROCHE	230
SALIX PHARMACEUTICALS	231
SANDOZ.....	231
SANOFI- AVENTIS	232
SHIONOGI PHARMA INC.....	233
SHIRE PLC	233
SOLVAY PHARMACEUTICALS SA	234

TARO PHARMACEUTICAL INDUSTRIES LTD.	234
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	235
UCB INC.	235
UNITED THERAPEUTICS.....	236
VALEANT PHARMACEUTICALS INTERNATIONAL	236
VIVUS INC.....	236
WATSON PHARMACEUTICALS.....	237
XANODYNE.....	238
ZYDUS PHARMA USA.....	238
APPENDIX I—ABBREVIATIONS AND DEFINITIONS.....	239
ABBREVIATIONS AND DEFINITIONS	239
ABBREVIATIONS AND DEFINITIONS (CONTINUED)	240